Hypoxia-inducible factor stabilizers : 27 228 patients studied, yet a role still undefined
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA..
With the emergence of hypoxia inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) came the hope that using these oral drugs could improve the treatment of the anemia of kidney disease. In this editorial we discuss the accumulated knowledge on these agents and the clinical context for use.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Clinical kidney journal - 16(2023), 5 vom: 15. Mai, Seite 776-779 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fishbane, Steven [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 09.05.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ckj/sfad026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356545520 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356545520 | ||
| 003 | DE-627 | ||
| 005 | 20231226070707.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ckj/sfad026 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356545520 | ||
| 035 | |a (NLM)37151410 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fishbane, Steven |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hypoxia-inducible factor stabilizers |b 27 228 patients studied, yet a role still undefined |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.05.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. | ||
| 520 | |a With the emergence of hypoxia inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) came the hope that using these oral drugs could improve the treatment of the anemia of kidney disease. In this editorial we discuss the accumulated knowledge on these agents and the clinical context for use | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a CKD | |
| 650 | 4 | |a ESA | |
| 650 | 4 | |a anemia | |
| 650 | 4 | |a chronic renal failure | |
| 650 | 4 | |a dialysis | |
| 700 | 1 | |a Malieckal, Deepa A |e verfasserin |4 aut | |
| 700 | 1 | |a Ng, Ji H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical kidney journal |d 2012 |g 16(2023), 5 vom: 15. Mai, Seite 776-779 |w (DE-627)NLM219739579 |x 2048-8505 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:5 |g day:15 |g month:05 |g pages:776-779 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ckj/sfad026 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 5 |b 15 |c 05 |h 776-779 | ||